“

It's early days but if this works we believe we could end up treating up to 40 percent of patients with ovarian or breast cancer and, importantly, we also have very strong pre clinical results in lung cancer, we are not only first but we are going to be first and alone for a time in DDR because there is nobody else that has this portfolio ... we will have something quite unique.